Aclaris Therapeutics, Inc.
ACRS
Jodie situation report
Aclaris Therapeutics, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 29 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 2 directly disclosed connections are confirming.
- ACRS's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if ACRS's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind ACRS
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
LLYEli Lilly and CompanypartnerFeb 26, 2026 ▾
“Under the royalty purchase agreement, we sold to OMERS a portion of the future royalty payments and the remaining anniversary payments associated with our existing license to Eli Lilly and Company (“Lilly”), relating to OLUMIANT® (baricitinib) for the treatme…”
MDPediatrix Medical Group, Inc.partnerFeb 26, 2026 ▾
“License Agreement with Pediatrix Therapeutics, Inc.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 7 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
ACRS is currently a Follower in the organic co-movement group Semiconductor Equipment. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 2 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for ACRS; it is not active in the latest market snapshot.